Search For "medalliance"
MedAlliance to be acquired by Cordis
Updated : 3 years, 5 months ago IST
Geneva [Switzerland], October 19 (ANI/PRNewswire): Swiss-based medical technology company MedAlliance has announced it has entered into an agreement with Cordis for an acquisition which includes an initial investment of USD 35M and upfront closing payment of USD 200M, regulatory achievement
Read More
First patient enrolled in Erectile Dysfunction prospective randomized stud
Updated : 3 years, 6 months ago IST
Geneva [Switzerland], September 10 (ANI/PRNewswire): An 82-year-old Taiwanese man has become the first patient to be enrolled in the initial Erectile Dysfunction (ED) randomized clinical trial (RCT) involving SELUTION SLR™, MedAlliance's novel sirolimus-eluting balloon.
Read More
First US patient enrolled in SELUTION SLR IDE Peripheral Study
Updated : 3 years, 7 months ago IST
Geneva [Switzerland], August 24 (ANI/PRNewswire): The first US patient has been enrolled in the FDA SELUTION4BTK (Below-the-Knee) clinical trial evaluating SELUTION SLR™, MedAlliance's novel sirolimus-eluting balloon. This milestone follows Investigational Device Exemption (IDE) approv
Read More
MedAlliance SELUTION SLR receives second FDA IDE approval
Updated : 3 years, 7 months ago IST
Geneva [Switzerland], August 10 (ANI/PRNewswire): SELUTION SLR™, MedAlliance's novel sirolimus-eluting balloon, has received conditional FDA Investigational Device Exemption (IDE) approval to initiate its pivotal clinical trial for the treatment of occlusive disease of the superficial
Read More
First patient enrolled in SELUTION SLR IDE BTK Study
Updated : 3 years, 9 months ago IST
Leipzig [Germany], June 8 (ANI/PRNewswire): The first patient has been enrolled in the FDA IDE BTK (Below-the-Knee) SELUTION4BTK clinical trial involving SELUTION SLR™, MedAlliance's novel sirolimus-eluting balloon, just one week after receiving IDE approval.
Read More
18-Month Below-the-Knee data with MedAlliance's SELUTION SLR™ presen
Updated : 4 years, 5 months ago IST
Geneva [Switzerland], October 11 (ANI/PRNewswire): 18-month results from the PRESTIGE* Below-the-Knee (BTK) study have been presented as a Late Breaking Clinical Trial at VIVA21.
Read More
MedAlliance announces completion of enrollment in Japanese SELUTION SLR
Updated : 4 years, 6 months ago IST
Geneva [Switzerland], September 23 (ANI/PRNewswire): MedAlliance, with its Japanese partner MDK Medical, has completed enrollment in the clinical study of its novel Sirolimus Drug Eluting Balloon (DEB), SELUTION SLR™, for the treatment of peripheral arterial disease (PAD).
Read More
MedAlliance announces first patient enrolled in the 3,300 Patient Landmark
Updated : 4 years, 6 months ago IST
Geneva [Switzerland], September 1 (ANI/PRNewswire): MedAlliance is pleased to announce the enrollment of the first patient in the ground-breaking coronary randomized controlled study "SELUTION DeNovo". This study utilizes SELUTION SLR™, a novel sirolimus drug-eluting balloon [DEB], ver
Read More
MedAlliance announces enrollment of first patient in erectile dysfunction
Updated : 4 years, 7 months ago IST
Nyon [Switzerland], August 19 (ANI/PRNewswire): MedAlliance has announced enrollment of the first patient in an erectile dysfunction (ED) feasibility study with its sirolimus drug-eluting balloon [DEB].
Read More
MedAlliance announces completion of enrolment in PRISTINE clinical trial w
Updated : 4 years, 7 months ago IST
Nyon [Switzerland], August 13 (ANI/PRNewswire): MedAlliance has announced completion of patient enrolment in the PRISTINE clinical trial with SELUTION SLR™ 018 DEB (drug-eluting balloon) for the treatment of patients with Below-the-Knee (BTK) disease.
Read More
First patient enrolled in SELUTION SLR™ SUCCESS PTA study
Updated : 5 years, 1 month ago IST
Nyon [Switzerland], February 11 (ANI/PRNewswire): MedAlliance has announced enrolment of the first patient in SUCCESS PTA, its large post-market study with the drug-eluting balloon SELUTION SLR™ for the treatment of patients with peripheral artery disease (PAD).
Read More
MedAlliance gains CE Mark approval for coronary SELUTION SLR™ Siroli
Updated : 5 years, 9 months ago IST
Mumbai (Maharashtra) [India] June 16 (ANI/PRNewswire): MedAlliance has announced the award of its second CE Mark: SELUTION SLR™ 014 PTCA, a novel Sirolimus Drug Eluting Balloon (DEB), for the treatment of coronary arterial disease.
Read More